*Study Objective: After repeated administration of BR1015-1 and BR1015-2 for healthy volunteers, the pharmacokinetic interactions and safety are evaluated.~*Investigational Product (and regimen)~BR1015-1: Administration of BR1015-1 60 mg once a day for 5 days~BR1015-2: Administration of BR1015-2 1.5 mg once a day for 5 days~BR1015-1+BR1015-2: Co-administration of BR1015-1 60 mg and BR1015-2 1.5 mg once a day for 5 days
The purpose of this study is to evaluate pharmacokinetic interactions (Drug-Drug interaction) and safety between BR1015-1 and BR1015-2 in healthy volunteers.